Osimertinib almost doubles PFS versus SOC for first line EGFR mutated lung cancer, from 10 to 18 months, at #ESMO17… https://t.co/0pgFCG00MM

Osimertinib almost doubles PFS versus SOC for first line EGFR mutated lung cancer, from 10 to 18 months, at #ESMO17… https://t.co/0pgFCG00MM

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://twitter.com/ecancer/status/909054505534279680
via IFTTT